Society of Gynecologic Oncology Annual Meeting on Women's Cancer (SGO 2023)
Tampa, Florida, US 25 March 2023 - 28 March 2023
Neoadjuvant olaparib feasible in BRCA-mutated ovarian cancer
Neoadjuvant treatment with the PARP* inhibitor olaparib yielded encouraging outcomes in patients with BRCA-mutated ovarian cancer, with all participants completing two cycles of therapy followed by surgery in the NOW trial presented at SGO 2023.
Neoadjuvant olaparib feasible in BRCA-mutated ovarian cancer
23 May 2023
Toripalimab plus bevacizumab, SoC demonstrates promising efficacy for cervical cancer
Preliminary results of a single-arm, open-label, phase II trial demonstrated the efficacy of a combination regimen comprising toripalimab, bevacizumab, and platinum-based chemotherapy for women with refractory, recurrent, or metastatic cervical cancer.
Toripalimab plus bevacizumab, SoC demonstrates promising efficacy for cervical cancer
15 May 2023
Can an antibody-drug conjugate alter the treatment landscape of difficult-to-treat ovarian cancer?
Mirvetuximab soravtansine (MIRV), an antibody drug conjugate (ADC), showed antitumour activity in women with platinum-resistant ovarian cancer* (PROC) with high folate receptor alpha (FRα) expression, findings from the phase III SORAYA study have shown.
Can an antibody-drug conjugate alter the treatment landscape of difficult-to-treat ovarian cancer?
20 Apr 2023
Add-on immunotherapy improves PFS in 1L advanced or recurrent endometrial cancer
Adding dostarlimab or pembrolizumab to standard first-line (1L) chemotherapy significantly improves progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer, two phase III trials have shown.